Visterra, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2007-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.visterrainc.com
Clinical Trials
20
Active:10
Completed:9
Trial Phases
2 Phases
Phase 1:13
Phase 2:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Phase 1
13 (72.2%)Phase 2
5 (27.8%)A Study to Evaluate Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Multiple Doses of VIS954
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Visterra, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06937593
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult Participants
Phase 1
Active, not recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Other: Placebo
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Visterra, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT06212804
- Locations
- 🇺🇸
Visterra Clinical Site, Anaheim, California, United States
A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and with Autoimmune Disease)
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Visterra, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT05418101
- Locations
- 🇧🇬
UMHAT, Plovdiv, Bulgaria
🇧🇬Ambulatory for Specialized Medical Help - skin and venereal diseases, Sofia, Bulgaria
🇧🇬Comac Medical Ltd, Sofia, Bulgaria
Safety and Efficacy Study of VIS649 for IgA Nephropathy
Phase 2
Completed
- Conditions
- Immunoglobulin A NephropathyGlomerular DiseaseIgAN
- Interventions
- Drug: Medium Dose-VIS649Drug: High Dose-VIS649Drug: Dose-PlaceboDrug: Low Dose-VIS649
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Visterra, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT04287985
- Locations
- 🇬🇧
Visterra Investigational Site, Salford, United Kingdom
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
Phase 1
Completed
- Conditions
- IgAN - IgA NephropathyIgA NephropathyImmunoglobulin A Nephropathy
- Interventions
- Biological: Placebo
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Visterra, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT03719443
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
- Prev
- 1
- 2
- Next
News
No news found